文献速递淋巴瘤

滤泡性淋巴瘤延长利妥昔单抗维持治疗:SAKK 35/03随机试验长期结果

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
PubMed 文献 · Blood Adv · 2020-01-01

The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03 randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules in patients with follicular lymphoma (FL). Here, we report their long-term treatment outcome.…

要点

  • 有症状需立即治疗患者10年总生存率达83%(95%CI 73-89)。

核心结论

  • 延长利妥昔单抗维持治疗随访10年未显示显著获益。
  • 单药利妥昔单抗可作为有症状晚期滤泡性淋巴瘤患者有效的一线选择。

研究设计与样本

  • 短期维持组82例接受4次利妥昔单抗(375 mg/m2,每2个月一次),长期维持组83例接受最长5年维持。
  • 主要终点为无事件生存期(EFS)。

主要发现

  • 无进展生存期和总生存期两组均无统计学显著差异。
  • 第二肿瘤发生率两组相似(短期维持组9例,长期维持组10例)。
  • 未出现重大晚期毒性。

关键数值与推荐

  • 有症状需立即治疗患者10年OS率为83%(95%CI 73-89%)。

临床怎么用

  • 对于有症状需立即治疗的晚期滤泡性淋巴瘤患者,单药利妥昔单抗可作为有效一线选择。
  • 延长利妥昔单抗维持治疗至5年未显著改善长期结局,临床决策需权衡获益与成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03 randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules in patients with follicular lymphoma (FL). Here, we report their long-term treatment outcome. Two-hundred and seventy FL patients were treated with 4 weekly doses of rituximab monotherapy (375 mg/m2); 165 of them, achieving at least a partial response, were randomly assigned to maintenance rituximab (375 mg/m2 every 2 months) on a short-term (4 administrations; n = 82) or a long-term (up to a maximum of 5 years; n = 83) schedule. The primary end point was event-free survival (EFS). At a median follow-up period of 10 years, median EFS was 3.4 years (95% confidence interval [CI], 2.1-5.5) in the short-term arm and 5.3 years (95% CI, 3.5-7.5) in the long-term arm. Using the prespecified log-rank test, this difference is not statistically significant (P = .39). There also was not a statistically significant difference in progression-free survival or overall survival (OS). Median OS was 11.0 years (95% CI, 11.0-NA) in the short-term arm and was not reached in the long-term arm (P = .80). The incidence of second cancers was similar in the 2 arms (9 patients after short-term maintenance and 10 patients after long-term maintenance). No major late toxicities emerged. No significant benefit of prolonged maintenance became evident with longer follow-up. Notably, in symptomatic patients in need of immediate treatment, the 10-year OS rate was 83% (95% CI, 73-89%). These findings indicate that single-agent rituximab may be a valid first-line option for symptomatic patients with advanced FL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moccia AA, Taverna C, Schär S, et al. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv. 2020. PMID: 33275769. doi:10.1182/bloodadvances.2020002858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。